HCA Healthcare Conference Call Summary Company Overview - **Company**: HCA Healthcare (NYSE:HCA) - **Event**: FY Conference on March 16, 2026 - **Key Speakers**: Jon Foster (EVP and COO), Christopher Wyatt (SVP and Controller), Frank Morgan (VP of IR) Key Points Business Performance - **2025 Performance**: - Achieved 47 million patient encounters - 2.4% year-over-year admission growth - EBITDA margin improved by 90 basis points to 20.6% [2][3] - **2026 Focus**: - Continued investment in digital and AI initiatives - Emphasis on financial resiliency and network optimization [3] Admission Trends - **Growth Confidence**: - Targeting 2%-3% admission growth driven by population and demand growth in 43 domestic markets [4] - **Capital Projects**: - Investing in inpatient capacity and expanding outpatient sites from 14 to at least 20 sites per hospital [5][6] Marketplace Dynamics - **Exchange Impact**: - Exchanges accounted for 8% of admissions and 10% of revenue in 2025 - Estimated headwind of $600 million to $900 million for 2026 due to potential loss of HIX volume [8][9] - **Utilization Assumptions**: - Anticipated decline in utilization for uninsured individuals [9][10] Pricing and Acuity - **Acuity Investments**: - Enhanced clinical capabilities in various services (e.g., organ transplants, trauma) [11] - **Contracting Status**: - 90% of contracts for 2026 finalized with expected price increases within anticipated ranges [12] Medicaid and State Programs - **Medicaid Volume**: - Anticipated return to average growth after recent declines due to redetermination processes [14] - **State Directed Payment Programs**: - Expected decline in net benefit of $250 million to $450 million year-over-year due to program pauses and retro payments [16][17] Labor and Cost Trends - **Labor Environment**: - Turnover rates and contract labor costs have returned to pre-pandemic levels [32] - **Physician Specialty Fees**: - High single-digit growth expected in hospital-based physician services [35] Capital Deployment Strategy - **Cash Flow**: - Generated $12.6 billion in 2025, projected between $12 billion and $13 billion in 2026 [36] - **Capital Allocation**: - Over $7 billion in capital projects planned, alongside M&A activities and share repurchases [36][38] AI and Technology Integration - **AI Utilization**: - Focus on administrative, operational, and clinical domains to enhance patient care and operational efficiency [26][30] - **Investment in Technology**: - Significant investments made to improve revenue cycle management and reduce denial impacts [24] Supply Chain Management - **Supply Expenses**: - Stable supply expense outlook with over two-thirds of pricing locked for 2026 [46][47] Investor Communication - **Competitive Advantage**: - Emphasis on scale and shared services platforms as key competitive advantages in local markets [49] Additional Insights - **Rural Hospital Fund**: - Monitoring opportunities under the $50 billion fund, with no immediate benefits assumed for 2026 [45] - **Regulatory Changes**: - Anticipated manageable impact from Medicaid cuts under OB3 due to phased implementation and company positioning in non-expansion states [19][20][21] This summary encapsulates the key insights and strategic directions discussed during the HCA Healthcare conference call, highlighting the company's performance, market dynamics, and future initiatives.

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant financial losses for investors during the specified Class Period [1][3]. Group 1: Allegations Against Ardent Health - The lawsuit claims that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, which inflated reported financial positions [3]. - It is alleged that Ardent Health's accounts receivable framework allowed for delayed recognition of losses, contributing to misleading financial reporting [3]. - The company reportedly lacked sufficient professional malpractice liability insurance and reserves to cover claims, particularly in the New Mexico market, which has seen increasing social inflationary pressures [3]. Group 2: Financial Impact and Stock Performance - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised accounts receivable collectability assessments and a new revenue accounting system [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million – $615 million to $530 million – $555 million, citing persistent industry-wide cost pressures [4]. - Following these announcements, Ardent Health's stock price fell nearly 34%, reflecting the negative market reaction to the disclosed financial issues [4]. Group 3: Class Action Process - Investors who purchased Ardent Health securities during the Class Period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5]. - The lead plaintiff has the authority to select a law firm for litigation and does not need to be the lead plaintiff to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in complex class action litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [6].

4Q25 Earnings Presentation March 4, 2026 Important Disclaimers Forward-Looking Statements Non-GAAP Financial Information We have included certain financial measures in this presentation that have not been prepared in a manner that complies with U.S. generally accepted accounting principles ("GAAP"), including Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EBITDAR, Adjusted EBITDAR margin and free cash flow, net of noncontrolling interest distributions. We define these terms as follows: Adjusted EBITDA an ...

Core Viewpoint - Ardent Health, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with significant financial implications for investors who acquired securities during the specified class period [1]. Summary by Relevant Sections Class Action Lawsuit Details - Investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, have until March 9, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1]. - The lawsuit alleges that Ardent Health and its executives made false or misleading statements regarding the company's financial practices and accounts receivable [1]. Allegations Against Ardent Health - The lawsuit claims that Ardent Health did not rely on detailed reviews of historical collections for determining the collectability of accounts receivable [1]. - It is alleged that the company utilized a 180-day cliff for accounts receivable, allowing it to report inflated amounts and delay loss recognition [1]. - The financial position reported by Ardent Health is claimed to be materially false and misleading due to insufficient professional malpractice liability insurance and reserves [1]. Financial Impact - On November 12, 2025, Ardent Health reported a $43 million decrease in third-quarter 2025 revenue, attributed to revised accounts receivable collectability determinations [1]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing persistent industry-wide cost pressures [1]. - Additionally, a $54 million increase in professional liability reserves was recorded due to recent settlements and ongoing litigation, influenced by broader industry trends [1]. - Following these announcements, Ardent Health's stock price fell nearly 34% [1].

Core Insights - Ardent Health Corporation (ARDT) is set to release its quarterly earnings on March 4, 2026, with analysts predicting an earnings per share (EPS) of $0.34 and revenue of approximately $1.63 billion [1][6] Legal Issues - ARDT is currently facing a securities fraud class action lawsuit due to undisclosed collections problems, which have resulted in a 33% decline in its stock value [2][6] - Investors who purchased securities between July 18, 2024, and November 12, 2025, are encouraged to file lead plaintiff applications by March 9, 2026 [2] Financial Metrics - The company has a price-to-earnings (P/E) ratio of 6.45, indicating a relatively low valuation compared to its earnings [3][6] - ARDT's price-to-sales ratio is 0.21, meaning investors pay 21 cents for every dollar of sales [3] - The enterprise value to sales ratio is 0.48, reflecting its valuation in relation to revenue [3] - The enterprise value to operating cash flow ratio stands at 8.28, suggesting a moderate valuation based on cash flow [4] - ARDT's earnings yield is 15.50%, providing a measure of return on investment for shareholders [4] - The debt-to-equity ratio of 1.84 indicates a significant reliance on debt in its capital structure [4][6] - The current ratio of 2.08 suggests a strong ability to cover short-term liabilities with short-term assets [5]

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and the adequacy of reserves, leading to significant financial losses for investors during the specified class period [1][3]. Summary by Sections Class Action Details - The lawsuit is titled Postiwala v. Ardent Health, Inc., and it allows purchasers of Ardent Health securities from July 18, 2024, to November 12, 2025, to seek lead plaintiff status by March 9, 2026 [1][2]. Allegations Against Ardent Health - The lawsuit claims that Ardent Health did not accurately assess the collectability of accounts receivable, using a 180-day cliff for reserving accounts, which inflated reported receivables [3]. - It is alleged that Ardent Health lacked sufficient professional malpractice liability insurance and reserves to cover increasing claims due to social inflation in the medical malpractice sector [3]. Financial Impact - On November 12, 2025, Ardent Health reported a $43 million decrease in Q3 2025 revenue due to revised accounts receivable assessments and announced a cut in 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million [4]. - The company also recorded a $54 million increase in professional liability reserves related to past claims, which contributed to a nearly 34% drop in stock price following the announcement [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ardent Health securities during the class period to seek lead plaintiff status, which enables them to represent the interests of the class [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, marking its fourth 1 ranking in five years [6].

Group 1 - Barclays has lowered its price target for Humana Inc. (HUM) from $245 to $176, maintaining an Equal Weight rating due to concerns about margin expansion expectations [1] - Humana has acquired MaxHealth, a Florida-based clinic operator, to integrate into its CenterWell Senior Primary Care division, expanding its primary care footprint for seniors [2][3] - The acquisition of MaxHealth, valued at around $1 billion, supports Humana's strategy to enhance its primary care network amid rising care costs and tighter government reimbursement rates [2][3] Group 2 - MaxHealth operates over 80 clinics in West and South Florida, serving more than 120,000 patients, which aligns with Humana's broader efforts in the Medicare Advantage business [3] - Humana operates through two main segments: Insurance and CenterWell, providing both insurance and healthcare services [3]

Core Viewpoint - Tenet Healthcare Corporation (NYSE:THC) is viewed as a strong buy in the healthcare sector, with multiple analysts raising their price targets following the release of its fiscal Q4 financial results and 2026 guidance [1][2]. Financial Performance - Tenet Healthcare reported a net income of $371 million for fiscal Q4, translating to $4.22 per diluted share. The adjusted diluted earnings per share for the quarter increased by 36.6% to $4.70, compared to $3.44 in the same period last year [2]. Analyst Ratings and Price Targets - Truist raised its price target for Tenet Healthcare to $270 from $240 on February 17, maintaining a Buy rating [1]. - Wells Fargo increased its price target to $265 from $229 on February 16, while keeping an Overweight rating, citing strong capital return potential and alignment with market narratives as key drivers [2]. Company Operations - Tenet Healthcare operates in the healthcare services sector, with its business divided into Hospital Operations and Ambulatory Care segments [3].

Company Performance - SelectQuote Inc. reported a 12% year-over-year revenue increase to $537 million for FQ2 2026, driven by strong performance in its senior segment and a 26% revenue jump for SelectRx [1] - The company secured a $415 million senior credit facility, refinancing its debt with extended maturities to 2031, improving overall capital flexibility [1] Financial Guidance - Despite revenue growth, the company lowered its FY2026 guidance due to a $40 million impact from a national carrier's marketing budget cuts and changes in pharmacy benefit manager (PBM) reimbursements [2] - The PBM shift is expected to create a $20 million headwind to 2026 EBITDA [2] - A new multi-year agreement with a major PBM signed in January is expected to provide greater stability and predictability in reimbursement rates [2] Market Position - The CEO emphasized that managing over 100,000 complex members has strengthened the company's negotiating position [3] - SelectQuote remains confident in its high-quality, diversified model to navigate market shifts better than competitors, despite industry concerns regarding CMS advance rate notices [3] Business Model - SelectQuote operates a technology-enabled, direct-to-consumer distribution and engagement platform that sells insurance policies and healthcare services in the US [4]

Core Insights - Healthcare costs significantly impact retirees' Social Security benefits, with many retirees reporting that medical expenses consume a large portion of their income [1][2]. Group 1: Financial Impact on Retirees - Out-of-pocket medical costs account for approximately one-third of a typical retiree's Social Security income and nearly a quarter of their total income [2]. - Some retirees report spending over $11,000 annually on healthcare services, including premiums for Medicare Part B and other supplements, challenging the notion of "free healthcare" under Medicare [3]. - A significant number of seniors have had to forgo medical care due to high costs, with over half of America's 55.8 million seniors skipping at least one healthcare product or service in the past year [4]. Group 2: Cost-of-Living Adjustments (COLA) - The current COLA formula is criticized for not accurately reflecting the rising healthcare costs faced by retirees, leading to a disconnect between income adjustments and actual expenses [5][6]. - The cost-of-living index used does not adequately track the specific medical expenses that retirees incur, which are a larger percentage of their yearly expenses compared to the general population [5].